Publications

Daptomycin antimicrobial activity tested against methicillin-resistant staphylococi and vancomycin-resistant enterococci isolated in European medical centers (2005). by Sader HS, Watters AA, Fritsche TR and Jones RN published in BMC Infect. Dis. 2007; 7 (1) : 29

Comment on: Occurrence prevalence and genetic environment of CTX-M beta-lactamases in Enterobacteriaceae from Indian hospitals. by Walsh TR, Toleman MA and Jones RN published in J. Antimicrob. Chemother. 2007; 59 (4): 799-800

Accuracies of beta-lactam susceptibility test results for Pseudomonas aeruginosa with four automated systems (BD Phoenix, MicroScan WalkAway, Vitek and Vitek 2). by Juretschko S, LaBombardi VJ, Lerner SA and Schreckenberger PC published in J. Clin. Microbiol. 2007; 45 (4): 1339-1342

Influence of polysorbate-80 when determining the tigecycline MIC by the reference method. by Jones RN, Knapp CC and Dowzicky MJ published in Diagn. Microbiol. Infect. Dis. 2007; 58 (1): 145-146

Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values. by Jones RN, Fritsche TR, Sader HS and Stilwell MG published in Diagn. Microbiol. Infect. Dis. 2007; 58 (1): 9-17

Garenoxacin activity against isolates from patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae. by Jones RN, Sader HS, Stilwell MG and Fritsche TR published in Diagn. Microbiol. Infect. Dis. 2007; 58 (1): 1-7

Potency and spectrum of garenoxacin tested against an international collection of skin and skin tissue infection pathogens: Report from the SENTRY Antimicrobial Surveillance Program (1999-2004). by Fritsche TR, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2007; 58 (1): 19-26

In vitro activity of garenoxacin tested against a worldwide collection of ciprofloxacin-susceptible and ciprofloxacin-resistant Enterobacteriaceae strains (1999-2004). by Sader HS, Fritsche TR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2007; 58 (1): 27-32

Prevalence and significance of a negative extended-spectrum beta-lactamase (ESBL) confirmation test result after a positive ESBL screening test reslt for isolates of Escherichia coli and Klebsiella pneumoniae: Results from the SENTRY Asia-Pacific Surveillance Program. by Bell JM, Chitsaz M, Turnidge JD, Barton M, walters LJ and Jones RN published in J. Clin. Microbiol. 2007; 45 (5): 1478-1482

Reevaluation of Clinical and Laboratory Standards Institute disk diffusion breakpoints for tetracyclines for testing Enterobacteriaceae. by Sader HS, Ferraro MJ, Reller LB, Schreckenberger PC, Swenson JM and Jones RN published in J. Clin. Microbiol. 2007; 45 (5): 1640-1643

Impact of drug-exposure intensity and duration of therapy on the emergence Staphylococcus aureus resistance to a quinolone antimicrobial. by Tam VH, Louie A, Fritsche TR, Deziel M, Liu W, Brown DL, Deshpande L, Leary R, Jones RN and Drusano GL published in J. Infect. Dis. 2007; 195 (12): 1818-1827

Evaluation of the in vitro activity of daptomycin against 19,615 clinical isolates of Gram-positive cocci collected in North American hospitals (2002-2005). by Pfaller MA, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2007; 57 (4): 459-465

Re-evaluation of the role of broad spectrum cephalosporins against staphylococci by applying contemporary in vitro results and pharmacokinetic/pharmacodynamic principles. by Sader HS, Bhavnani SM, Ambrose PG, Jones RN and Pfaller MA published in J. Chemother. 2007; 19 (1): 38-43

Oral β-lactams applied to uncomplicated infections of skin and skin structures. by Jacobs MR, Jones RN and Giordano PA published in Diagn. Microbiol. Infect. Dis. 2007; 57 (Suppl 3): 55S-65S

Activity of linezolid against 3,251 strains of uncommonly isolated Gram-positive organisms: Report from the SENTRY Antimicrobial Surveillance Program. by Jones RN, Stilwell MG, Hogan PA and Sheehan DJ published in Antimicrob. Agents Chemother. 2007; 51 (4): 1491-1493

Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes. by Toleman MA, Bennett PM, Bennett DMC, Jones RN and Walsh TR published in Emerg. Inf. Dis. 2007; 13 (4): 559-565

Activity of dalbavancin tested against Staphylococcus spp. and β-haemolytic Staphylococcus spp. isolated from 52 geographically diverse medical centers in the United States. by Biedenbach DJ, Ross JE, Fritsche TR, Sader HS and Jones RN published in J. Clin. Microbiol. 2007; 45 (3): 998-1004

Bactericidal activity of cefepime and ceftriaxone tested against Streptococcus pneumoniae. by Pottumarthy S, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2007; 57 (3): 345-349

Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype. by Sader HS, Hsiung A, Fritsche TR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2007; 57 (3): 341-344

Tigecycline (GAR-936) activity against Streptococcus gallolyticus (bovis) and viridans group streptococci. by Moet GJ, Dowzicky MJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2007; 57 (3): 333-336

Oxazolidinone susceptibility patterns for 2005: International report from the Zyvox®; Annual Appraisal of Potency and Spectrum Study. by Ross JE, Fritsche TR, Sader HS and Jones RN published in Int. J. Antimicrob. Agents 2007; 29 (3): 295-301

bla_VIM-2 and bla_VIM-7 carbapenemase-producing Pseudomonas aeruginosa isolates detected in a tertiary care medical center in the United States: Report from the MYSTIC Program. by Aboufaycal H, Sader HS, Deshpande LM, Toleman M, Bodey G, Raad I and Jones RN published in J. Clin. Microbiol. 2007; 45: 614-615

Cefdinir: An oral cephalosporin for the treatment of respiratory tract infections and skin and skin structure infections. by Sader HS and Jones RN published in Expert Rev. Anti. Infect. Ther. 2007; 5 (1): 29-43

Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC Program report from the Unite States component (2005). by Rhomberg PR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2007; 57 (2): 207-215

Multicenter studies of tigecycline disk diffusions susceptibility results for Acinetobacter spp. by Jones RN, Ferraro MJ, Reller LB, Schreckenberger PC, Swenson JM and Sader HS published in J. Clin. Microbiol. 2007; 45 (1): 227-230

Contemporary causes of skin and soft tissue infections in North America, Latin America and Europe: Report from the SENTRY Antimicrobial Surveillance Program (1998-2004). by Moet GJ, Jones RN, Biedenbach DJ, Stilwell MG and Fritsche TR published in Diagn. Microbiol. Infect. Dis. 2007; 57 (1): 7-13

Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: Report from the SENTRY Antimicrobial Surveillance Program (1998-2004). by Jones RN, Sader HS, Fritsche TR and Pottumarthy S published in Diagn. Microbiol. Infect. Dis. 2007; 57 (1): 109-116

Serial sinus aspirate samples during high-dose, short course levofloxacin treatment of acute maxillary sinusitis. by Anon JB, Paglia M, Xiang J, Ambrose PG, Jones RN and Kahn JB published in Diagn. Microbiol. Infect. Dis. 2007; 57 (1): 105-107

In Vitro Activity of a Novel Carbapenem, Doripenem, Tested Against Bacterial Pathogens Recovered from Patients Hospitalized with Pneumonia (North America; 2003-2005), Lead author: Fritsche TR, presented at 44th annual Infectious Diseases Society of America (IDSA), October 12 – 15, 2006, Toronto, Ontario, Canada

Antimicrobial Activity of Broad-Spectrum &#223-Lactams, Including Doripenem, Tested Against Bloodstream Infection Isolates: A Global Surveillance Report (2003-2005), Lead author: Fritsche TR, presented at 44th annual Infectious Diseases Society of America (IDSA), October 12 – 15, 2006, Toronto, Ontario, Canada

Evaluation of Daptomycin Activity Tested against 34,603 Bacterial Strains from Hospitalized Patients: Summary of a 4 Year Surveillance Program for North America and Europe (2002-2005), Lead author: Jones RN, presented at 44th annual Infectious Diseases Society of America (IDSA), October 12 – 15, 2006, Toronto, Ontario, Canada

Activity of Daptomycin and Selected Antimicrobial Agents against Staphylococcus aureus Isolated from Patients with Bacteremia in North America: A Four Year Analysis, Lead author: Sader HS, presented at 44th annual Infectious Diseases Society of America (IDSA), October 12 – 15, 2006, Toronto, Ontario, Canada

Re-Evaluation of the Cefdinir Activity Tested Against Contemporary Isolates from Skin and Soft Tissue Infections (SSTI; 2005), Lead author: Sader HS, presented at 44th annual Infectious Diseases Society of America (IDSA), October 12 – 15, 2006, Toronto, Ontario, Canada

Comparison of Cefepime and Ceftriaxone Bactericidal Activity Against Streptococcus pneumoniae, Lead author: Sader HS, presented at 44th annual Infectious Diseases Society of America (IDSA), October 12 – 15, 2006, Toronto, Ontario, Canada

Comparative Activity of Broad-Spectrum Antimicrobial Agents Used in the Treatment of Serious Infections Caused by Non-Enteric Gram Negative Bacilli: Seventh Year Report from the MYSTIC Program (USA; 1999-2005), Lead author: Jones RN, presented at 44th annual Infectious Diseases Society of America (IDSA), October 12 – 15, 2006, Toronto, Ontario, Canada

Antimicrobial Activity of Tigecycline and Other Broad-Spectrum Agents Tested Against Bloodstream Infection Isolates Collected Worldwide, Lead author: Sader HS, presented at 44th annual Infectious Diseases Society of America (IDSA), October 12 – 15, 2006, Toronto, Ontario, Canada

In Vitro Activity of Tigecycline Tested Against Pneumonia Pathogens from Hospitalized Patients: Results from a Global Surveillance Program (2004-2005), Lead author: Fritsche TR, presented at 44th annual Infectious Diseases Society of America (IDSA), October 12 – 15, 2006, Toronto, Ontario, Canada

Pneumococcal Conjugate Vaccine (PCV7) Effect on Antibiograms: Serotype and Susceptibility (S) Rate Changes in the SENTRY Antimicrobial Surveillance Program (USA), Lead author: Jones RN, presented at 44th annual Infectious Diseases Society of America (IDSA), October 12 – 15, 2006, Toronto, Ontario, Canada

A Mathematical Model for the Impact of the Conjugate Vaccine on S. pneumoniae Vaccine and Non-vaccine serotypes, Lead author: Mera RM, presented at 44th annual Infectious Diseases Society of America (IDSA), October 12 – 15, 2006, Toronto, Ontario, Canada

Carbapenem Resistances Among P. aeruginosa Isolated in an USA Medical Center: Report of Osteomyelitis Caused by an IMP-15 Producing Strain, Lead author: Jones RN, presented at 44th annual Infectious Diseases Society of America (IDSA), October 12 – 15, 2006, Toronto, Ontario, Canada

Potency and Spectrum of DC-159a Tested Against More Than 800 Recent Clinical Isolates, Lead author: Jones RN, presented at 46th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2006, San Francisco, California

DC-159a, a Novel Oral Quinolone, Activity Tested Against Community-Acquired Respiratory Tract (CA-RTI) Pathogens, Lead author: Jones RN, presented at 46th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2006, San Francisco, California

Comparative In Vitro Activity of DC-159a, a New Oral Fluoroquinolone, Against Viridans Streptococci, Lead author: Smith K, presented at 46th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2006, San Francisco, California

In Vitro Activity of Nine Developmental Cationic Steroid Compounds (Ceragenins) Against Clinical Isolates of Clostridium difficile, Lead author: Fritsche TR, presented at 46th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2006, San Francisco, California

In Vitro Activity of DX-619 Compared to Other Agents against Viridans Streptococci, Lead author: Smith K, presented at 46th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2006, San Francisco, California

Pneumococcal Conjugate Vaccine Effect on S. pneumoniae Serotype Carriage and Multidrug-Resistance in the United States, Lead author: Mera RM, presented at 46th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2006, San Francisco, California

Antimicrobial Activity of Tigecycline (TIG) Tested Against Serine Carbapenemase-Producing Enterobacteriaceae Isolated in the United States, Lead author: Sader HS, presented at 46th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2006, San Francisco, California

Molecular and Epidemiologic Characterization of Community-Associated Methicillin-Resistant S. aureus (CA-MRSA) Isolated from North American Medical Centers: Report from The SENTRY Program (2000- 2004), Lead author: Deshpande LM, presented at 46th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2006, San Francisco, California

Molecular Characterization of S. aureus (SA) Isolates from a Contemporary (2005) Clinical Trial of Uncomplicated Skin and Skin Structure Infections (uSSSI), Lead author: Jones RN, presented at 46th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2006, San Francisco, California

Antimicrobial Activity of Tigecycline against Community-Acquired Methicillin-Resistant S. aureus (CA-MRSA) Isolated in North American Medical Centers, Lead author: Jones RN, presented at 46th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, 2006, San Francisco, California